



# Pharmaceutical Biotechnology

Concepts  
and Applications

Gary Walsh




 WILEY

# Pharmaceutical Biotechnology

Concepts and Applications

**Gary Walsh**

*University of Limerick, Republic of Ireland*



John Wiley & Sons, Ltd

Copyright © 2007 John Wiley & Sons Ltd, The Atrium, Southern Gate, Chichester,  
West Sussex PO19 8SQ, England

Telephone (+44) 1243 779777

Email (for orders and customer service enquiries): [cs-books@wiley.co.uk](mailto:cs-books@wiley.co.uk)  
Visit our Home Page on [www.wileyeurope.com](http://www.wileyeurope.com) or [www.wiley.com](http://www.wiley.com)

All Rights Reserved. No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, scanning or otherwise, except under the terms of the Copyright, Designs and Patents Act 1988 or under the terms of a licence issued by the Copyright Licensing Agency Ltd, 90 Tottenham Court Road, London W1T 4LP, UK, without the permission in writing of the Publisher. Requests to the Publisher should be addressed to the Permissions Department, John Wiley & Sons Ltd, The Atrium, Southern Gate, Chichester, West Sussex PO19 8SQ, England, or emailed to [permreq@wiley.co.uk](mailto:permreq@wiley.co.uk), or faxed to (+44) 1243 770620.

Designations used by companies to distinguish their products are often claimed as trademarks. All brand names and product names used in this book are trade names, service marks, trademarks or registered trademarks of their respective owners. The Publisher is not associated with any product or vendor mentioned in this book.

This publication is designed to provide accurate and authoritative information in regard to the subject matter covered. It is sold on the understanding that the Publisher is not engaged in rendering professional services. If professional advice or other expert assistance is required, the services of a competent professional should be sought.

#### ***Other Wiley Editorial Offices***

John Wiley & Sons Inc., 111 River Street, Hoboken, NJ 07030, USA

Jossey-Bass, 989 Market Street, San Francisco, CA 94103-1741, USA

Wiley-VCH Verlag GmbH, Boschstr. 12, D-69469 Weinheim, Germany

John Wiley & Sons Australia Ltd, 42 McDougall Street, Milton, Queensland 4064, Australia

John Wiley & Sons (Asia) Pte Ltd, 2 Clementi Loop #02-01, Jin Xing Distripark, Singapore 129809

John Wiley & Sons Canada Ltd, 6045 Freemont Blvd, Mississauga, Ontario, L5R 4J3

Wiley also publishes its books in a variety of electronic formats. Some content that appears in print may not be available in electronic books.

Anniversary Logo Design: Richard J. Pacifico

#### ***Library of Congress Cataloging-in-Publication Data***

Walsh, Gary, Dr.

Pharmaceutical biotechnology : concepts and applications / Gary Walsh.

p. ; cm.

Includes bibliographical references.

ISBN 978-0-470-01244-4 (cloth)

1. Pharmaceutical biotechnology. I. Title.

[DNLN: 1. Technology, Pharmaceutical. 2. Biotechnology. 3.

Pharmaceutical Preparations. QV 778 W224p 2007]

RS380.W35 2007

615'.19--dc22

2007017884

#### ***British Library Cataloguing in Publication Data***

A catalogue record for this book is available from the British Library

ISBN 978-0-470-01244-4 (HB)

ISBN 978-0-470-01245-1 (PB)

Typeset in 10.5/12.5 pt Times by Thomson Digital

Printed and bound in Great Britain by Antony Rowe Ltd., Chippenham, Wilts

This book is printed on acid-free paper responsibly manufactured from sustainable forestry in which at least two trees are planted for each one used for paper production.

I dedicate this book to my beautiful daughter Alice.  
To borrow a phrase:

*'without her help, it would have been written in half the time'!*



# Preface

This book has been written as a sister publication to *Biopharmaceuticals: Biochemistry and Biotechnology*, a second edition of which was published by John Wiley and Sons in 2003. The latter textbook caters mainly for advanced undergraduate/postgraduate students undertaking degree programmes in biochemistry, biotechnology and related disciplines. Such students have invariably pursued courses/modules in basic protein science and molecular biology in the earlier parts of their degree programmes; hence, the basic principles of protein structure and molecular biology were not considered as part of that publication. This current publication is specifically tailored to meet the needs of a broader audience, particularly to include students undertaking programmes in pharmacy/pharmaceutical science, medicine and other branches of biomedical/clinical sciences. Although evolving from *Biopharmaceuticals: Biochemistry and Biotechnology*, its focus is somewhat different, reflecting its broader intended readership. This text, therefore, includes chapters detailing the basic principles of protein structure and molecular biology. It also increases/extends the focus upon topics such as formulation and delivery of biopharmaceuticals, and it contains numerous case studies in which both biotech and clinical aspects of a particular approved product of pharmaceutical biotechnology are overviewed. The book, of course, should also meet the needs of students undertaking programmes in core biochemistry, biotechnology or related scientific areas and be of use as a broad reference source to those already working within the pharmaceutical biotechnology sector.

As always, I owe a debt of gratitude to the various people who assisted in the completion of this textbook. Thanks to Sandy for her help in preparing various figures, usually at ridiculously short notice. To Gerard Wall, for all the laughs and for several useful discussions relating to molecular biology. Thank you to Nancy, my beautiful wife, for accepting my urge to write (rather than to change baby's nappies) with good humour – most of the time anyway! I am also grateful to the staff of John Wiley and Sons for their continued professionalism and patience with me when I keep overrunning submission deadlines. Finally, I have a general word of appreciation to all my colleagues at the University of Limerick for making this such an enjoyable place to work.

**Gary Walsh**  
November 2006

# Acronyms

ADCC	antibody-dependent cell cytotoxicity
BAC	bacterial artificial chromosome
BHK	baby hamster kidney
cDNA	complementary DNA
CHO	Chinese hamster ovary
CNTF	ciliary neurotrophic factor
CSF	colony-stimulating factor
dsRNA	double-stranded RNA
EDTA	ethylenediaminetetraacetic acid
ELISA	enzyme-linked immunosorbent assay
EPO	erythropoietin
FGF	fibroblast growth factor
FSH	follicle-stimulating hormone
GDNF	glial cell-derived neurotrophic factor
GH	growth hormone
hCG	human chorionic gonadotrophin
HIV	human immunodeficiency virus
HPLC	high-performance liquid chromatography
IGF	insulin-like growth factor
ISRE	interferon-stimulated response element
JAK	Janus kinase
LAF	lymphocyte activating factor
LIF	leukaemia inhibitory factor
LPS	lipopolysaccharide
MHC	major histocompatibility complex
MPS	mucopolysaccharidosis
mRNA	messenger RNA
PDGF	platelet-derived growth factor
PEG	polyethylene glycol

PTK	protein tyrosine kinase
PTM	post-translational modification
rDNA	recombinant DNA
RNAi	RNA interference
rRNA	ribosomal RNA
SDS	sodium dodecyl sulfate
ssRNA	single-stranded RNA
STATs	signal transducers and activators of transcription
TNF	tumour necrosis factor
tPA	tissue plasminogen activator
tRNA	transfer RNA
WAP	whey acid protein
WFI	water for injections

# Contents

<b>Preface</b>	<b>xv</b>
<b>Acronyms</b>	<b>xvii</b>
<b>1 Pharmaceuticals, biologics and biopharmaceuticals</b>	<b>1</b>
1.1 Introduction to pharmaceutical products	1
1.2 Biopharmaceuticals and pharmaceutical biotechnology	1
1.3 History of the pharmaceutical industry	2
1.4 The age of biopharmaceuticals	3
1.5 Biopharmaceuticals: current status and future prospects	8
Further reading	11
<b>2 Protein structure</b>	<b>13</b>
2.1 Introduction	13
2.2 Overview of protein structure	13
2.2.1 Primary structure	15
2.2.2 The peptide bond	18
2.2.3 Amino acid sequence determination	19
2.2.4 Polypeptide synthesis	22
2.3 Higher level structure	23
2.3.1 Secondary structure	23
2.3.2 Tertiary structure	26
2.3.3 Higher structure determination	26
2.4 Protein stability and folding	27
2.4.1 Structural prediction	28
2.5 Protein post-translational modification	29
2.5.1 Glycosylation	29
2.5.2 Carboxylation and hydroxylation	33
2.5.3 Sulfation and amidation	34
Further reading	35
<b>3 Gene manipulation and recombinant DNA technology</b>	<b>37</b>
3.1 Introduction	37
3.2 Nucleic acids: function and structure	38
3.2.1 Genome and gene organization	41
3.2.2 Nucleic acid purification	43
3.2.3 Nucleic acid sequencing	45
3.3 Recombinant production of therapeutic proteins	46
3.4 Classical gene cloning and identification	47
3.4.1 cDNA cloning	51
3.4.2 Cloning via polymerase chain reaction	51



3.4.3	Expression vectors	53
3.4.4	Protein engineering	53
	Further reading	54
<b>4</b>	<b>The drug development process</b>	<b>57</b>
4.1	Introduction	57
4.2	Discovery of biopharmaceuticals	58
4.3	The impact of genomics and related technologies upon drug discovery	59
4.4	Gene chips	61
4.5	Proteomics	62
4.6	Structural genomics	64
4.7	Pharmacogenetics	65
4.8	Initial product characterization	66
4.9	Patenting	67
4.9.1	What is a patent and what is patentable?	68
4.9.2	Patenting in biotechnology	68
4.10	Delivery of biopharmaceuticals	70
4.10.1	Oral delivery systems	70
4.10.2	Pulmonary delivery	71
4.10.3	Nasal, transmucosal and transdermal delivery systems	73
4.11	Preclinical studies	74
4.12	Pharmacokinetics and pharmacodynamics	74
4.12.1	Protein pharmacokinetics	75
4.12.2	Tailoring of pharmacokinetic profile	77
4.12.3	Protein mode of action and pharmacodynamics	79
4.13	Toxicity studies	80
4.13.1	Reproductive toxicity and teratogenicity	82
4.13.2	Mutagenicity, carcinogenicity and other tests	83
4.13.3	Clinical trials	84
4.13.4	Clinical trial design	87
4.13.5	Trial size design and study population	87
4.14	The role and remit of regulatory authorities	89
4.14.1	The Food and Drug Administration	90
4.14.2	The investigational new drug application	92
4.14.3	The new drug application	94
4.14.4	European regulations	95
4.14.5	National regulatory authorities	96
4.14.6	The European Medicines Agency and the new EU drug approval systems	96
4.14.7	The centralized procedure	98
4.14.8	Mutual recognition	100
4.14.9	Drug registration in Japan	100
4.14.10	World harmonization of drug approvals	101
4.15	Conclusion	101
	Further reading	101
<b>5</b>	<b>Sources and upstream processing</b>	<b>105</b>
5.1	Introduction	105
5.2	Sources of biopharmaceuticals	105
5.2.1	<i>Escherichia coli</i> as a source of recombinant, therapeutic proteins	105
5.2.2	Expression of recombinant proteins in animal cell culture systems	109

5.2.3	Additional production systems	110
5.2.3.1	Yeast	110
5.2.3.2	Fungal production systems	111
5.2.3.3	Transgenic animals	111
5.2.3.4	Transgenic plants	116
5.2.3.5	Insect cell-based systems	118
5.3	Upstream processing	120
5.3.1	Cell banking systems	121
5.3.2	Microbial cell fermentation	124
5.3.3	Mammalian cell culture systems	127
	Further reading	129
<b>6</b>	<b>Downstream processing</b>	<b>131</b>
6.1	Introduction	131
6.2	Initial product recovery	134
6.3	Cell disruption	134
6.4	Removal of nucleic acid	136
6.5	Initial product concentration	137
6.5.1	Ultrafiltration	137
6.5.2	Diafiltration	139
6.6	Chromatographic purification	140
6.6.1	Size-exclusion chromatography (gel filtration)	142
6.6.2	Ion-exchange chromatography	142
6.6.3	Hydrophobic interaction chromatography	146
6.6.4	Affinity chromatography	148
6.6.5	Immunoaffinity purifications	150
6.6.6	Protein A chromatography	150
6.6.7	Lectin affinity chromatography	150
6.6.8	Dye affinity chromatography	152
6.6.9	Metal chelate affinity chromatography	153
6.6.10	Chromatography on hydroxyapatite	154
6.6.11	Chromatofocusing	155
6.7	High-performance liquid chromatography of proteins	155
6.8	Purification of recombinant proteins	157
6.9	Final product formulation	159
6.9.1	Some influences that can alter the biological activity of proteins	159
6.9.1.1	Proteolytic degradation and alteration of sugar side-chains	160
6.9.1.2	Protein deamidation	161
6.9.1.3	Oxidation and disulfide exchange	162
6.9.2	Stabilizing excipients used in final product formulations	164
6.9.3	Final product fill	166
6.9.4	Freeze-drying	168
6.9.5	Labelling and packing	169
	Further reading	171
<b>7</b>	<b>Product analysis</b>	<b>173</b>
7.1	Introduction	173
7.2	Protein-based contaminants	173
7.3	Removal of altered forms of the protein of interest from the product stream	175
7.3.1	Product potency	175

7.3.2	Determination of protein concentration	179
7.4	Detection of protein-based product impurities	180
7.4.1	Capillary electrophoresis	182
7.4.2	High-performance liquid chromatography	183
7.4.3	Mass spectrometry	184
7.5	Immunological approaches to detection of contaminants	185
7.5.1	Amino acid analysis	185
7.5.2	Peptide mapping	186
7.5.3	N-terminal sequencing	188
7.5.4	Analysis of secondary and tertiary structure	188
7.6	Endotoxin and other pyrogenic contaminants	189
7.6.1	Endotoxin, the molecule	191
7.6.2	Pyrogen detection	191
7.6.3	DNA	195
7.6.4	Microbial and viral contaminants	196
7.6.5	Viral assays	198
7.6.6	Miscellaneous contaminants	199
7.6.7	Validation studies	199
	Further reading	202
<b>8</b>	<b>The cytokines: The interferon family</b>	<b>205</b>
8.1	Cytokines	205
8.1.1	Cytokine receptors	210
8.1.2	Cytokines as biopharmaceuticals	211
8.2	The interferons	212
8.2.1	The biochemistry of interferon- $\alpha$	213
8.2.2	Interferon- $\beta$	214
8.2.3	Interferon- $\gamma$	214
8.2.4	Interferon signal transduction	214
8.2.5	The interferon receptors	215
8.2.6	The JAK-STAT pathway	215
8.2.7	The interferon JAK-STAT pathway	218
8.2.8	The biological effects of interferons	219
8.2.9	The eIF-2 $\alpha$ protein kinase system	221
8.3	Interferon biotechnology	224
8.3.1	Production and medical uses of interferon- $\alpha$	226
8.3.2	Medical uses of interferon- $\beta$	229
8.3.3	Medical applications of interferon- $\gamma$	232
8.3.4	Interferon toxicity	234
8.3.5	Additional interferons	235
8.4	Conclusion	236
	Further reading	237
<b>9</b>	<b>Cytokines: Interleukins and tumour necrosis factor</b>	<b>241</b>
9.1	Introduction	241
9.2	Interleukin-2	242
9.2.1	Interleukin-2 production	246
9.2.2	Interleukin-2 and cancer treatment	246
9.2.3	Interleukin-2 and infectious diseases	248
9.2.4	Safety issues	249
9.2.5	Inhibition of interleukin-2 activity	249

9.3	Interleukin-1	251
9.3.1	The biological activities of interleukin-1	252
9.3.2	Interleukin-1 biotechnology	253
9.4	Interleukin-11	254
9.5	Tumour necrosis factors	255
9.5.1	Tumour necrosis factor biochemistry	255
9.5.2	Biological activities of tumour necrosis factor- $\alpha$	256
9.5.3	Immunity and inflammation	257
9.5.4	Tumour necrosis factor receptors	258
9.5.5	Tumour necrosis factor: therapeutic aspects	260
	Further reading	262
<b>10</b>	<b>Growth factors</b>	<b>265</b>
10.1	Introduction	265
10.2	Haematopoietic growth factors	265
10.2.1	The interleukins as haematopoietic growth factors	268
10.2.2	Granulocyte colony-stimulating factor	269
10.2.3	Macrophage colony-stimulating factor	269
10.2.4	Granulocyte macrophage colony-stimulating factor	270
10.2.5	Clinical application of colony-stimulating factors	270
10.2.6	Erythropoietin	272
10.2.6.1	Therapeutic applications of erythropoietin	274
10.2.6.2	Chronic disease and cancer chemotherapy	278
10.2.7	Thrombopoietin	278
10.3	Growth factors and wound healing	279
10.3.1	Insulin-like growth factors	280
10.3.2	Insulin-like growth factor biological effects	281
10.3.3	Epidermal growth factor	282
10.3.4	Platelet-derived growth factor	283
10.3.5	Fibroblast growth factors	284
10.3.6	Transforming growth factors	284
10.3.7	Neurotrophic factors	286
	Further reading	287
<b>11</b>	<b>Therapeutic hormones</b>	<b>291</b>
11.1	Introduction	291
11.2	Insulin	291
11.2.1	Diabetes mellitus	292
11.2.2	The insulin molecule	293
11.2.3	The insulin receptor and signal transduction	294
11.2.4	Insulin production	294
11.2.5	Production of human insulin by recombinant DNA technology	297
11.2.6	Formulation of insulin products	297
11.2.7	Engineered insulins	301
11.2.8	Additional means of insulin administration	304
11.3	Glucagon	305
11.4	Human growth hormone	307
11.4.1	The growth hormone receptor	307
11.4.2	Biological effects of growth hormone	308
11.4.3	Therapeutic uses of growth hormone	309

11.5	The gonadotrophins	310
11.5.1	Follicle-stimulating hormone, luteinizing hormone and human chorionic gonadotrophin	311
11.5.2	Pregnant mare serum gonadotrophin	315
11.5.3	The inhibins and activins	315
11.6	Medical and veterinary applications of gonadotrophins	319
11.6.1	Sources and medical uses of follicle-stimulating hormone, luteinizing hormone and human chorionic gonadotrophin	319
11.6.2	Recombinant gonadotrophins	320
11.6.3	Veterinary uses of gonadotrophins	321
11.7	Additional recombinant hormones now approved	323
11.8	Conclusion	325
	Further reading	325
<b>12</b>	<b>Recombinant blood products and therapeutic enzymes</b>	<b>329</b>
12.1	Introduction	329
12.2	Haemostasis	329
12.2.1	The coagulation pathway	330
12.2.2	Terminal steps of coagulation pathway	332
12.2.3	Clotting disorders	334
12.2.4	Factor VIII and haemophilia	335
12.2.5	Production of factor VIII	336
12.2.6	Factors IX, IIVa and XIII	339
12.3	Anticoagulants	340
12.3.1	Hirudin	342
12.3.2	Antithrombin	344
12.4	Thrombolytic agents	345
12.4.1	Tissue plasminogen activator	346
12.4.2	First-generation tissue plasminogen activator	348
12.4.3	Engineered tissue plasminogen activator	348
12.4.4	Streptokinase	350
12.4.5	Urokinase	350
12.4.6	Staphylokinase	351
12.4.7	$\alpha_1$ -Antitrypsin	353
12.4.8	Albumin	354
12.5	Enzymes of therapeutic value	355
12.5.1	Asparaginase	355
12.5.2	DNase	357
12.5.3	Glucocerebrosidase	359
12.5.4	$\alpha$ -Galactosidase, urate oxidase and laronidase	360
12.5.5	Superoxide dismutase	363
12.5.6	Debriding agents	364
12.5.7	Digestive aids	364
	Further reading	366
<b>13</b>	<b>Antibodies, vaccines and adjuvants</b>	<b>371</b>
13.1	Introduction	371
13.2	Traditional polyclonal antibody preparations	371
13.3	Monoclonal antibodies	374
13.3.1	Antibody screening: phage display technology	376
13.3.2	Therapeutic application of monoclonal antibodies	378

13.3.3	Tumour immunology	379
13.3.3.1	Antibody-based strategies for tumour detection/destruction	383
13.3.3.2	Drug-based tumour immunotherapy	386
13.3.3.3	First-generation anti-tumour antibodies: clinical disappointment	388
13.3.4	Tumour-associated antigens	389
13.3.5	Antigenicity of murine monoclonals	391
13.3.6	Chimaeric and humanized antibodies	392
13.3.7	Antibody fragments	394
13.3.8	Additional therapeutic applications of monoclonal antibodies	395
13.4	Vaccine technology	396
13.4.1	Traditional vaccine preparations	396
13.4.1.1	Attenuated, dead or inactivated bacteria	398
13.4.1.2	Attenuated and inactivated viral vaccines	399
13.4.1.3	Toxoids and antigen-based vaccines	399
13.4.2	The impact of genetic engineering on vaccine technology	400
13.4.3	Peptide vaccines	402
13.4.4	Vaccine vectors	403
13.4.5	Development of an AIDS vaccine	407
13.4.6	Difficulties associated with vaccine development	409
13.4.7	AIDS vaccines in clinical trials	409
13.4.8	Cancer vaccines	410
13.4.9	Recombinant veterinary vaccines	411
13.5	Adjuvant technology	412
13.5.1	Adjuvant mode of action	413
13.5.2	Mineral-based adjuvants	413
13.5.3	Oil-based emulsion adjuvants	414
13.5.4	Bacteria/bacterial products as adjuvants	414
13.5.5	Additional adjuvants	415
	Further reading	416
<b>14</b>	<b>Nucleic-acid- and cell-based therapeutics</b>	<b>419</b>
14.1	Introduction	419
14.2	Gene therapy	419
14.2.1	Basic approach to gene therapy	420
14.2.2	Some additional questions	423
14.3	Vectors used in gene therapy	424
14.3.1	Retroviral vectors	424
14.3.2	Adenoviral and additional viral-based vectors	428
14.3.3	Manufacture of viral vectors	431
14.3.4	Non-viral vectors	432
14.3.5	Manufacture of plasmid DNA	436
14.4	Gene therapy and genetic disease	438
14.5	Gene therapy and cancer	441
14.6	Gene therapy and AIDS	444
14.6.1	Gene-based vaccines	444
14.6.2	Gene therapy: some additional considerations	445
14.7	Antisense technology	445
14.7.1	Antisense oligonucleotides and their mode of action	446
14.7.2	Uses, advantages and disadvantages of 'oligos'	448

14.8	Oligonucleotide pharmacokinetics and delivery	450
14.8.1	Manufacture of oligos	451
14.8.2	Additional antigene agents: RNA interference and ribozymes	451
14.9	Aptamers	453
14.10	Cell- and tissue-based therapies	453
14.10.1	Stem cells	457
14.10.2	Adult stem cells	459
14.11	Conclusion	460
	Further reading	460

**Index****465**

# 1

## Pharmaceuticals, biologics and biopharmaceuticals

### 1.1 Introduction to pharmaceutical products

Pharmaceutical substances form the backbone of modern medicinal therapy. Most traditional pharmaceuticals are low molecular weight organic chemicals (Table 1.1). Although some (e.g. aspirin) were originally isolated from biological sources, most are now manufactured by direct chemical synthesis. Two types of manufacturing company thus comprise the 'traditional' pharmaceutical sector: the chemical synthesis plants, which manufacture the raw chemical ingredients in bulk quantities, and the finished product pharmaceutical facilities, which purchase these raw bulk ingredients, formulate them into final pharmaceutical products, and supply these products to the end user.

In addition to chemical-based drugs, a range of pharmaceutical substances (e.g. hormones and blood products) are produced by/extracted from biological sources. Such products, some major examples of which are listed in Table 1.2, may thus be described as products of biotechnology. In some instances, categorizing pharmaceuticals as products of biotechnology or chemical synthesis becomes somewhat artificial. For example, certain semi-synthetic antibiotics are produced by chemical modification of natural antibiotics produced by fermentation technology.

### 1.2 Biopharmaceuticals and pharmaceutical biotechnology

Terms such as 'biologic', 'biopharmaceutical' and 'products of pharmaceutical biotechnology' or 'biotechnology medicines' have now become an accepted part of the pharmaceutical literature. However, these terms are sometimes used interchangeably and can mean different things to different people.

Although it might be assumed that 'biologic' refers to any pharmaceutical product produced by biotechnological endeavour, its definition is more limited. In pharmaceutical circles, 'biologic' generally refers to medicinal products derived from blood, as well as vaccines, toxins and allergen products. 'Biotechnology' has a much broader and long-established meaning. Essentially, it refers



**Table 1.1** Some traditional pharmaceutical substances that are generally produced by direct chemical synthesis

Drug	Molecular formula	Molecular mass	Therapeutic indication
Acetaminophen (paracetamol)	$C_8H_9NO_2$	151.16	Analgesic
Ketamine	$C_{13}H_{16}C/NO$	237.74	Anaesthetic
Levamisole	$C_{11}H_{12}N_2S$	204.31	Anthelmintic
Diazoxide	$C_8H_7C/N_2O_2S$	230.7	Antihypertensive
Acyclovir	$C_8H_{11}N_5O_3$	225.2	Antiviral agent
Zidovudine	$C_{10}H_{13}N_5O_4$	267.2	Antiviral agent
Dexamethasone	$C_{22}H_{29}FO_5$	392.5	Anti-inflammatory and immunosuppressive agent
Misoprostol	$C_{22}H_{38}O_5$	382.5	Anti-ulcer agent
Cimetidine	$C_{10}H_{16}N_6$	252.3	Anti-ulcer agent

to the use of biological systems (e.g. cells or tissues) or biological molecules (e.g. enzymes or antibodies) for/in the manufacture of commercial products.

The term 'biopharmaceutical' was first used in the 1980s and came to describe a class of therapeutic proteins produced by modern biotechnological techniques, specifically via genetic engineering (Chapter 3) or, in the case of monoclonal antibodies, by hybridoma technology (Chapter 13). Although the majority of biopharmaceuticals or biotechnology products now approved or in development are proteins produced via genetic engineering, these terms now also encompass nucleic-acid-based, i.e. deoxyribonucleic acid (DNA)- or ribonucleic acid (RNA)-based products, and whole-cell-based products.

### 1.3 History of the pharmaceutical industry

The pharmaceutical industry, as we now know it, is barely 60 years old. From very modest beginnings, it has grown rapidly, reaching an estimated value of US\$100 billion by the mid 1980s. Its current value is likely double or more this figure. There are well in excess of 10 000 pharmaceutical companies in existence, although only about 100 of these can claim to be of true international significance. These companies manufacture in excess of 5000 individual pharmaceutical substances used routinely in medicine.

**Table 1.2** Some pharmaceuticals that were traditionally obtained by direct extraction from biological source material. Many of the protein-based pharmaceuticals mentioned are now also produced by genetic engineering

Substance	Medical application
Blood products (e.g. coagulation factors)	Treatment of blood disorders such as haemophilia A or B
Vaccines	Vaccination against various diseases
Antibodies	Passive immunization against various diseases
Insulin	Treatment of diabetes mellitus
Enzymes	Thrombolytic agents, digestive aids, debriding agents (i.e. cleansing of wounds)
Antibiotics	Treatment against various infections agents
Plant extracts (e.g. alkaloids)	Various, including pain relief